Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis continues to deliver strong sales growth and core margin expansi…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Fri, 05/31/2024 – 14:19
Read more about Latest analysis of No…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Fri, 05/31/2024 – 14:19
Read more about Latest analysis of No…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04
Read more about Novartis Scembl…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04
Read more about Novartis Scembl…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Fri, 05/31/2024 – 00:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Sat, 05/25/2024 – 12:19
Read more about Novartis atrasentan Phase III data show clinica…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Sat, 05/25/2024 – 12:19
Read more about Novartis atrasentan Phase III data show clinica…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Sat, 05/25/2024 – 12:04…
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis
Thu, 05/16/2024 – 11:34
Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
…
